摘要
目的 :评价海捷亚 ( L OS+ HCTZ)、氯沙坦 ( L OS)及依那普利 ( ENA)的降压效果及安全性。方法 :选取轻中度高血压病 ( EH)患者 90例 ,随机分为 3组 ,分别测定 L OS+ HCTZ组、L OS组及 ENA组治疗前后的收缩压 /舒张压、血尿酸、尿素氮、肌酐及钾钠氯。结果 :L OS+ HCTZ组、L OS组及 ENA组治疗前后的收缩压 /舒张压均有明显差异 ( P <0 .0 1) ;L OS+ HCTZ的降压效果明显优于 L OS及 ENA( P <0 .0 1) ;L OS有明显的降低血尿酸的效果 ( P <0 .0 1) ;ENA导致干咳发生率较高。结论 :L OS+
Objective: A clinical study of LOS+HCTZ compared with losartan and Enalaprilat was conducted to evaluate its safety and efficacy in treating hypertension. Method: 90 cases of mild and moderate hypertension were divided into three groups by randomized. The data of systolic pressure/diastolic pressure, serum Uric Acid, Urea nitrogen, creatinine and K +, Na +, Cl - about the pretreatment and post-treatment in the three groups were respectively estimated. Result: The study demonstrated that there was obviously difference between the pretreatment and post-treatment in the three groups (P<0.01). The LOS+HCTZ was obviously superior to Losartan and Enalaprilat in efficacy in treating hypertension (P<0.01). LOS had the obvious result in decrease of serum Uric Acid, the incidence of dry cough was highest in Enalaprilat. Conclusion: The result demonstrated that LOS+HCTZ was the most effective and safety drug.
出处
《天津药学》
2003年第2期29-30,共2页
Tianjin Pharmacy
